CD44 and neoplasm: oHA’s unique molecular structure enables it to target tumor cells and inflammatory sites via receptor-mediated endocytosis (e.g., CD44 and RHAMM receptors), which improves drug delivery precision and therapeutic efficacy [19,20,21,22].